Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Change in Taxes (2016 - 2025)

Historic Change in Taxes for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to $296.6 million.

  • Gsk's Change in Taxes fell 5030.44% to $296.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 2347.69%. This contributed to the annual value of $1.5 billion for FY2025, which is 11809.77% up from last year.
  • Latest data reveals that Gsk reported Change in Taxes of $296.6 million as of Q4 2025, which was down 5030.44% from $420.9 million recorded in Q3 2025.
  • In the past 5 years, Gsk's Change in Taxes ranged from a high of $642.9 million in Q4 2023 and a low of -$95.0 million during Q2 2021
  • Its 5-year average for Change in Taxes is $295.9 million, with a median of $323.5 million in 2023.
  • In the last 5 years, Gsk's Change in Taxes tumbled by 13808.21% in 2021 and then skyrocketed by 3249458.74% in 2025.
  • Gsk's Change in Taxes (Quarter) stood at -$62.0 million in 2021, then soared by 994.71% to $554.8 million in 2022, then rose by 15.88% to $642.9 million in 2023, then fell by 7.17% to $596.8 million in 2024, then crashed by 50.3% to $296.6 million in 2025.
  • Its Change in Taxes was $296.6 million in Q4 2025, compared to $420.9 million in Q3 2025 and $321.5 million in Q2 2025.